<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01435200</url>
  </required_header>
  <id_info>
    <org_study_id>IV iron 2</org_study_id>
    <nct_id>NCT01435200</nct_id>
  </id_info>
  <brief_title>Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy</brief_title>
  <official_title>Prevention of Blood Transfusion With Intravenous Iron in Gynecologic Cancer Patients Receiving Platinum Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Can intravenous iron lower the rate of blood transfusion in gynecologic cancer patients
      receiving platinum based chemotherapy than oral iron?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anemia is a common condition during chemotherapy administration. Treatment options usually
      include oral iron supplementation and blood transfusion. However, oral iron has
      gastrointestinal side effects, which affects patient compliance, and only a small amount of
      oral iron can be absorbed from the gastrointestinal tract. Intravenous iron may overcome a
      block of iron absorption and iron recycling induced by hepcidin. Therefore, it may increase
      hemoglobin level and reduced blood transfusion in cancer patients receiving chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Red blood cell (RBC) transfusion rate</measure>
    <time_frame>6 months</time_frame>
    <description>The requirement of red blood cell transfusion before administration of chemotherapy will be evaluated for 6 cycles of chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total number of red blood transfusion units and number of cycles requiring blood transfusion</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Gynecologic Cancer</condition>
  <arm_group>
    <arm_group_label>Intravenous iron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iron sucrose 200 mg intravenous infusion in 15 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral iron</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ferrous fumarate 200 mg oral three times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous iron</intervention_name>
    <description>Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy</description>
    <arm_group_label>Intravenous iron</arm_group_label>
    <arm_group_label>Oral iron</arm_group_label>
    <other_name>Venofer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20-70 years

          -  Good performance status (Zubrod score &lt; 2)

          -  No serious underlying disease

          -  Normal renal function test

          -  Normal liver function test

          -  Platinum based chemotherapy is the first line regimen

          -  No prior or receiving radiotherapy

        Exclusion Criteria:

          -  Iron hypersensitivity

          -  Underlying disease which has the risk of iron overload such as chronic kidney disease,
             major thalassemia

          -  Progressive disease

          -  Bone marrow metastasis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarinee Manchana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chulalongkorn Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2011</study_first_submitted>
  <study_first_submitted_qc>September 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2011</study_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Tarinee Manchana</investigator_full_name>
    <investigator_title>Department of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>Intravenous iron</keyword>
  <keyword>gynecologic cancer blood transfusion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

